Verrica Pharmaceuticals VRCA 深 沪
等待开盘 10-08 09:30:00 美东时间
4.61
-0.080
-1.71%
华盛通- 最 高4.73
- 今 开4.66
- 成交量 220.65万股
- 最 低 4.46
- 昨 收 4.69
- 总市值 4354.51万
- 52周最高 17.382
- 市盈率 静 --
- 换手率 23.36%
- 52周最低 3.816
- 委 比 0.00%
- 总股本 944.58万
- 历史最高 232.90
- 量 比 44.33
- 振 幅 5.76%
- 历史最低 3.816
- 每 手 1
- 风险率 2.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Verrica Pharmaceuticals To Present Phase 2 Data On VP-315 For Basal Cell Carcinoma At SITC 2025 Annual Meeting
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting
今天 04:08
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Verrica Pharmaceuticals will present VP-315, an investigational oncolytic peptide for basal cell carcinoma, at the SITC 40th Annual Meeting. Both oral and poster presentations will discuss Phase 2 trial results assessing local immune activation post-treatment. The oral presentation is on November 5-9, 2025, in Maryland, with a 12:46–12:54 p.m. ET slot. VP-315, which induces immunogenic cell death, has shown promising immune responses in trials an...
10-07 20:05
Verrica Pharmaceuticals shares are trading higher after development partner Torii Pharmaceutical received Japan approval for YCANTH to treat molluscum contagiosum, triggering a $10M payment to Verrica.
Verrica Pharmaceuticals shares are trading higher after development partner Tor...
09-19 20:04
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals announced that its partner, Torii Pharmaceutical Co. Ltd., has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat molluscum contagiosum. This approval triggered a $10 million milestone payment to Verrica and addresses an unmet need for patients in Japan. Verrica retains global rights for YCANTH outside of Japan. The company plans to leverage this funding to support U.S. commercial activities an...
09-19 12:00
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Verrica Pharmaceuticals Inc.'s CEO, Jayson Rieger, will speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York City. The event includes a live webcast accessible via provided links. Verrica focuses on dermatology treatments, notably YCANTH® (VP-102) for molluscum contagiosum and common warts, and collaborates with Lytix Biopharma AS on VP-315 for non-melanoma skin cancers.
09-02 11:00
Verrica Pharmaceuticals Q2 Adj. EPS $0.25 Beats $(0.07) Estimate, Sales $12.702M Beat $4.367M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.07) by 457.14 percent. This is a 180.65 percent increase over losses of $(0.31) per
08-13 04:02
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
What to Expect from Verrica Pharmaceuticals's Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) is preparing to release its quarterly ear...
08-12 04:03
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Verrica Pharmaceuticals Inc. will host a conference call on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update. Participants can join via phone using the conference ID: VERRICA or access the live webcast on www.verrica.com. A replay will be available for 90 days. Verrica develops dermatology treatments, including YCANTH® for molluscum contagiosum and common warts, and VP-315 for non-melanoma s...
08-06 11:00
Verrica Reports Record 13,434 YCANTH Applicator Units Dispensed In Q2 2025, Marking 32.8% Sequential Growth
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q2 2025 –– Company reports receipt of $8 million milestone payment from its Japanese
07-09 19:05
